The past year has brought sweeping changes in the legalization and regulation of cannabis markets. In January, US Attorney General Jeff Sessions sounded an alarm by rescinding the Cole Memo. Over the following months, states in the US began taking action against shops selling CBD products. But, as the year begins to close, we’ve seen a great positive shift in the industry, with the FDA’s approval of the first CBD medicine for pediatric epilepsy and subsequent de-scheduling. We’ve also witnessed the full legalization of cannabis in Canada and recent ruling on the prohibition of cannabis in Mexico. As we head in 2019, global markets will undoubtedly continue to evolve.